American Journal of Clinical Dermatology

, Volume 6, Issue 1, pp 39–47 | Cite as

The Role of Dimethylaminoethanol in Cosmetic Dermatology

  • Rachel Grossman
Review Article


Skincare formulations for the improvement of aging skin are increasingly important consumer products. Here, we review available data on one such agent — 2-dimethylaminoethanol (DMAE) or deanol — that has recently been evaluated in a placebo-controlled trial. DMAE is an analog of the B vitamin choline and is a precursor of acetylcholine. Although the role of acetylcholine as a neurotransmitter is well known, growing evidence points to acetylcholine as a ubiquitous cytokine-like molecule that regulates basic cellular processes such as proliferation, differentiation, locomotion, and secretion in a paracrine and autocrine fashion. Indeed, this modulatory role may contribute to the cutaneous activity of DMAE.

In a randomized clinical study, 3% DMAE facial gel applied daily for 16 weeks has been shown to be safe and efficacious (p < 0.05) in the mitigation of forehead lines and periorbital fine wrinkles, and in improving lip shape and fullness and the overall appearance of aging skin. These effects did not regress during a 2-week cessation of application. Beneficial trends (p > 0.05 but ≤ 0.1) were noted in the appearance of coarse wrinkles, under-eye dark circles, nasolabial folds, sagging neck skin, and neck firmness. Application was found to be well tolerated, with no differences in the incidence of erythema, peeling, dryness, itching, burning, or stinging between the DMAE and placebo groups. An open-label extension of the trial showed that the long-term application of DMAE gel for up to 1 year was associated with a good safety profile. The acute skin-firming effects of DMAE have been confirmed by quantitative measures of cutaneous tensile strength. In vitro studies in peripheral blood lymphocytes indicate that DMAE is a moderately active anti-inflammatory agent. Although its mechanisms of action in the skin remain to be elucidated, evidence suggests that the skin is an active site of acetylcholine synthesis, storage, secretion, metabolism, and receptivity. Muscarinic acetylcholine receptors have been localized to keratinocytes, melanocytes and dermal fibroblasts, whereas nicotinic acetylcholine receptors have been found in keratinocytes. The role of acetylcholine and the role of DMAE as a modulator of acetylcholine-mediated functions in the skin remain to be elucidated.

Thus, the benefits of DMAE in dermatology include a potential anti-inflammatory effect and a documented increase in skin firmness with possible improvement in underlying facial muscle tone. Studies are needed to evaluate the relative efficacy of DMAE compared with other skin-care regimens (e.g., topical antioxidant creams, α-hydroxy acids).


Acetylcholine Tretinoin DMAE Facial Skin Aging Skin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dr Rachel Grossman is an employee of Johnson & Johnson and receives compensation, which includes common stock. Dr Grossman is also in private practice and has no other conflicts of interest that are directly relevant to the contents of this review.


  1. 1.
    Perricone N. The wrinkle cure: unlock the power of cosmeceuticals for supple youthful skin. Emmaus (PA): Rodale Press, 2000Google Scholar
  2. 2.
    Re O. 2-Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Ther Res. 1974; 16 (11): 1238–42PubMedGoogle Scholar
  3. 3.
    Flood JF, Smith GE, Cherkin A. Memory retention: potentiation of cholinergic drug combinations in mice. Neurobiol Aging. 1983; 4 (1): 37–43PubMedCrossRefGoogle Scholar
  4. 4.
    Saccar CL. Drug therapy in the treatment of minimal brain dysfunction. Am J Hosp Pharm. 1978; 35 (5): 544–52PubMedGoogle Scholar
  5. 5.
    Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. Clin Pharmacol Ther. 1975; 17 (5): 534–40PubMedGoogle Scholar
  6. 6.
    Artom C, Marietta C. Determination of dimethylaminoethanol in biological materials. Fed Proc. 1949; 8: 180–1Google Scholar
  7. 7.
    Wessler I, Kirkpatrick CJ, Racké K. Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological system: expression and function in humans. Pharmacol Ther. 1998; 77 (1): 59–79PubMedCrossRefGoogle Scholar
  8. 8.
    Wessler I, Kirkpatrick CJ, Racké K. The cholinergic ‘pitfall’: acetylcholine, a universal cell molecule in biological systems, including humans. Clin Exp Pharmacol Physiol. 1999; 26 (3): 198–205PubMedCrossRefGoogle Scholar
  9. 9.
    Haubrich DR, Gerber NH, Pflueger AB. Deanol affects choline metabolism in peripheral tissues of mice. J Neurochem. 1981; 37 (2): 476–82PubMedCrossRefGoogle Scholar
  10. 10.
    Haubrich DR, Wang PF, Clody DE, et al. Increase in rat brain acetylcholine induced by choline or deanol. Life Sci. 1975; 17: 975–80PubMedCrossRefGoogle Scholar
  11. 11.
    Grando SA, Kist DA, Qi M, et al. Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol. 1993; 101: 32–6PubMedCrossRefGoogle Scholar
  12. 12.
    Data on file, Johnson & Johnson, 2000Google Scholar
  13. 13.
    Nagy I, Nagy K. On the role of cross-linking of cellular proteins in aging. Mech Ageing De. 1980; 14 (1-2): 245–51CrossRefGoogle Scholar
  14. 14.
    Nagy I, Floyd RA. Electron spin resonance spectroscopic demonstration of the hydroxyl free radical scavenger properties of dimethylaminoethanol in spi n trapping experiments confirming the molecular basis for the biological effects of centrophenoxine. Arch Gerontol Geriar. 1984; 3 (4): 297–310CrossRefGoogle Scholar
  15. 15.
    Nag K Dajk G Ura I, et al. Comparative studies on the free radical scavenger properties of two nootropic drugs, CPH and BCE-00. An n NY Acad. 1994; 717: 115–21CrossRefGoogle Scholar
  16. 16.
    Zs-Nay I. Pharmacological interventions against aging through the cell plasma membrane: a review of the experimental results obtained in animals and human. Ann NY Acad. 2002; 959: 308–20CrossRefGoogle Scholar
  17. 17.
    Grossmn, Gisoli, Coe C. Safety and efficacy evaluation of a new skin firming technology: dimethylethanol and tyrosine. 60th Annual Meeting of the Academy of Dermatology; 2002 Feb 22-27; New OrleansGoogle Scholar
  18. 18.
    Grossman RM, Gisoldi EM, Cole CA. Long-term safety and efficacy evaluation of a new skin firming technology: dimethylethanol. 60th Annual Meeting of the Academy of Dermatology; 2002 Feb 22-27; New OrleansGoogle Scholar
  19. 19.
    Uhoda I, Faska N, Robert C, et al. Split face study on the cutaneous tensile effect of 2-dimethylaminoethanol (deanol) gel. Skin Res Technol. 2002; 8 (3): 164–7PubMedCrossRefGoogle Scholar
  20. 20.
    Hermanns-Lê T, Jonlet F, Scheen A, et al. Age and body mass index-related changes in cutaneous shear wave velocity. Exp Gerontol. 2001; 36: 363–72PubMedCrossRefGoogle Scholar
  21. 21.
    Data on file, Johnson & Johnson, 1999Google Scholar
  22. 22.
    Grando SA, Horton RM. The keratinocyte cholinergic system with acetylcholine as an epidermal cytotransmitter. Curr Opin Dermatol. 1997; 4: 262–8Google Scholar
  23. 23.
    Arredondo J, Hall LL, Ndoye A, et al. Central role of fibroblast alpha3 nicotinic acerylcholine receptor in mediating cutaneous effects of nicotine. Lab Invest. 2003; 83 (2): 207–25PubMedGoogle Scholar
  24. 24.
    Grando SA, Kist DA, Qi M, et al. Human keratinocytes synthesize, secrete, and degrade acetylcholine. J Invest Dermatol. 1993; 101 (1): 32–6PubMedCrossRefGoogle Scholar
  25. 25.
    Hoffmann K, Grate F, Wohlrab W, et al. Functional characterization of a high-affinity choline transport system in human keratinocytes. J Invest Dermatol. 2002; 119 (1): 118–21PubMedCrossRefGoogle Scholar
  26. 26.
    Allard WJ, Sigal IS, Dixon RA. Sequence of the gene encoding the human MI muscarinic acetylcholine receptor. Nucleic Acids Res. 1987; 15 (24): 10604PubMedCrossRefGoogle Scholar
  27. 27.
    Hosey MM. Diversity of structure, signaling and regulation within the family of muscarinic cholinergic receptors. FASEB J. 1992; 6 (3): 845–52PubMedGoogle Scholar
  28. 28.
    Mei L, Roeske WR, Yamamura HI. Molecular pharmacology of muscarinic receptor heterogeneity. Life Sci. 1989; 45: 1831–52PubMedCrossRefGoogle Scholar
  29. 29.
    Grando SA, Zelickson BD, Kist DA, et al. Keratinocyte muscarinic acerylcholine receptors: immunolocalization and partial characterization. J Invest Dermatol. 1995; 104 (1): 95–100PubMedCrossRefGoogle Scholar
  30. 30.
    Ndoye A, Buchli R, Greenberg B, et al. Identification and mapping of keratinocyte muscarinic acetylcholine receptor subtypes in human epidermis. J Invest Dermatol. 1998; 111 (3): 410–6PubMedCrossRefGoogle Scholar
  31. 31.
    Grando SA, Horton RM, Pereira EF, et al. A nicotinic acetylcholine receptor regulating cell adhesion and motility is expressed in human keratinocytes. J Invest Dermatol. 1995; 105 (6): 774–81PubMedCrossRefGoogle Scholar
  32. 32.
    Grando SA. Receptor-mediated action in human skin. Int J Dermatol. 2001; 40: 691–3PubMedCrossRefGoogle Scholar
  33. 33.
    Grando SA, Horton RM, Mauro TM, et al. Activation of keratinocyte nicotinic cholinergic receptors stimulates calcium influx and enhances cell differentiation. J Invest Dermatol. 1996; 107 (3): 412–8PubMedCrossRefGoogle Scholar
  34. 34.
    Nguyen VT, Ndoye A, Hall LL, et al. Programmed cell death of keratinocytes culminates in apoptotic secretion of a humectant upon secretagogue action of acetylcholine. J Cell Sci. 2001; 114: 1189–204PubMedGoogle Scholar
  35. 35.
    Buchli R, Ndoye A, Arredondo J, et al. Identification and characterization of muscarinic acetylcholine receptor subtypes expressed in human skin melanocytes. Mot Cell Biochem. 2001; 228 (1-2): 57–72CrossRefGoogle Scholar
  36. 36.
    Buchli R, Ndoye A, Rodriguez JG, et al. Human skin fibroblasts express m2, m4, and m5 subtypes of muscarinic acetylcholine receptors. J Cell Biochem. 1999; 74 (2): 264–77PubMedCrossRefGoogle Scholar
  37. 37.
    Kirkpatrick CJ, Bittinger F, Unger RE, et al. The non-neuronal cholinergic system in the endothelium: evidence and possible pathobiological significance. Jpn J Pharmacol. 2001; 85: 24–8PubMedCrossRefGoogle Scholar
  38. 38.
    Grando SA. Biological functions of keratinocyte cholinergic receptors. J Invest Dermatol Symp Proc. 1997; 2: 41–8Google Scholar
  39. 39.
    Baumgartner MK, Wei J, Aronstam RS. Retinoic acid-induced differentiation of a human blastoma cell line alters muscarinic receptor expression. Brain Res Dev Brain Res. 1993; 72: 305–8PubMedCrossRefGoogle Scholar
  40. 40.
    Haddad EB, Rousell J, Mak JC, et al. Transforming growth factor-beta 1 induces transcriptional down-regulation of m2 muscarinic receptor gene expression. Mot Pharmacol. 1996; 49 (5): 781–7Google Scholar
  41. 41.
    Fisher GJ, Wong S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol. 2002; 138: 1462–70PubMedCrossRefGoogle Scholar
  42. 42.
    Varani J, Wagner RL, Gharaee-Kermani M, et al. Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol. 2000; 114: 480–6PubMedCrossRefGoogle Scholar
  43. 43.
    Kang S, Fisher GJ, Voorhees JJ. Photoaging: pathogenesis, prevention, and treatment. Clin Geriatr Med. 2001; 17 (4): 643–59, v–viPubMedCrossRefGoogle Scholar
  44. 44.
    El-Domyati M, Attia S, Saleh F, et al. Intrinsic aging vs photoaging: a comparative histopathological, immunohistochemical, and ultrastructural study of skin. Exp Dermatol. 2002; 11 (5): 398–405PubMedCrossRefGoogle Scholar
  45. 45.
    Pierard-Franchimont C, Cornil F, Dehavay J, et al. Climacteric skin ageing of the face: a prospective longitudinal comparative trial on the effect of oral hormone replacement therapy. Maturitas. 1999; 32 (2): 87–93PubMedCrossRefGoogle Scholar
  46. 46.
    Clark III CP. New directions in skin care. Clin Plast Surg. 2001; 28 (4): 745–50PubMedGoogle Scholar
  47. 47.
    Katsambas AD, Katoulis AC. Topical retinoids in the treatment of aging of the skin. Adv Exp Med Biol. 1999; 455: 477–82PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Rachel Grossman
    • 1
  1. 1.Johnson & Johnson Consumer and Personal Products WorldwideSkillmanUSA

Personalised recommendations